Press Room

DDL 2022

Start
Wednesday, December 07, 2022 - 09:00
End
Friday, December 09, 2022 - 09:00
Location: Scotland, UK
Booth Number: 244

 

Visit Hovione’s booth at DDL next December 7-9 in Edinburgh and connect with one of our Inhalation Experts.

Schedule a meeting today
DDL – Drug Delivery to the Lungs
Stand #244

 

Hovione is a specialist integrated CDMO offering services for drug substance, drug product intermediate and drug product for oral and inhaled solutions. When looking for a fully Integrated Solution Provider for Inhalation, Hovione offers Customized high-performance APIs, Particle Engineering and Formulation along with a full range of highly specialized, innovative Inhalation Devices

Let’s discuss your project from feasibility to commercial.
 

 

In Edinburgh don’t miss Hovione’s poster presentations:

#39 - Evaluation of Performance of Dry Powder Inhaler Formulations by Laser Diffraction

Luís Sousa, Senior Analytical Scientist, R&D Analytical Development, Analytical Methodologies and Method Development

#48 - Capsule Filling of Spray Dried Powders for Inhalation using a Drum Filling technology: From Lab to Pilot Scale

Rui Churro, Scientist, R&D Inhalation & Advanced Drug Delivery, Process Development

#51 - Enhanced engineered formulations in dry powder inhalers for high dose lung delivery

Susana Saldanha, Manager, R&D Inhalation & Advanced Drug Delivery, Formulation Development

#53 - Simulation lung dissolution – fast-tracking DPI development

Hovione scientists with Inhalation Sciences

 

Schedule a meeting today

 

Find more about DDL2022

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026